Biodesix, Inc. (NASDAQ:BDSX) Receives $3.06 Average Target Price from Analysts

Shares of Biodesix, Inc. (NASDAQ:BDSX) have been assigned an average recommendation of “Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $3.06.

A number of research analysts recently issued reports on the stock. Craig Hallum started coverage on shares of Biodesix in a report on Friday, July 26th. They issued a “buy” rating and a $3.00 price objective for the company. Scotiabank assumed coverage on shares of Biodesix in a research note on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target for the company.

Biodesix Stock Down 3.6 %

Shares of BDSX opened at $1.34 on Friday. Biodesix has a one year low of $1.15 and a one year high of $2.21. The company has a market cap of $194.54 million, a P/E ratio of -3.44 and a beta of 1.22. The company has a debt-to-equity ratio of 0.99, a current ratio of 3.28 and a quick ratio of 3.28. The firm has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $1.61.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings data on Friday, November 1st. The company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $18.15 million for the quarter, compared to the consensus estimate of $18.45 million. Biodesix had a negative return on equity of 369.89% and a negative net margin of 66.84%. During the same quarter last year, the business posted ($0.12) EPS. Research analysts forecast that Biodesix will post -0.36 EPS for the current fiscal year.

Institutional Trading of Biodesix

A number of large investors have recently bought and sold shares of BDSX. CVI Holdings LLC acquired a new stake in Biodesix during the 2nd quarter worth about $59,000. Opaleye Management Inc. grew its holdings in Biodesix by 7.7% during the 1st quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after acquiring an additional 38,157 shares during the period. Perkins Capital Management Inc. grew its stake in shares of Biodesix by 74.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after buying an additional 310,000 shares during the period. Essex Investment Management Co. LLC grew its stake in shares of Biodesix by 1.4% in the 1st quarter. Essex Investment Management Co. LLC now owns 925,614 shares of the company’s stock valued at $1,324,000 after buying an additional 12,669 shares during the period. Finally, Farallon Capital Management LLC acquired a new stake in shares of Biodesix in the 2nd quarter valued at about $2,874,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.